Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 17Carboplatin 10Paclitaxel 7Trastuzumab 5Nivolumab 5Gemcitabine 5Early Intervention, Educational 5Cyclophosphamide 5Cisplatin 5fludarabine 4cemiplimab 4Psychiatric Rehabilitation 4Fluorouracil 4Docetaxel 4Counseling 4Albumin-Bound Paclitaxel 4tisotumab vedotin 3belinostat 3Radiotherapy 3Polymerase Chain Reaction 3Methods 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Fluorodeoxyglucose F18 3Biopsy 3zimberelimab 2ulixertinib 2pertuzumab 2palbociclib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Lenalidomide × Gynecologic × Clear all
NCT01352962 2026-04-14

Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡